Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St futures muted as investors monitor US-Iran negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Acadia Pharmaceuticals (ACAD) PT Lowered to $26 at RBC Capital
August 7, 2024 6:24 AM EDTRBC Capital analyst Gregory Renza lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $26.00 (from $29.00) while maintaining a Outperform rating.
The analyst comments "Daybue miss representative of launch growing pains, in our view, as new patient starts fall short of Street (and even... More
